Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia.
“We are pleased to receive this prestigious honor, and thankful to our partners, Families Fighting Flu and several collegiate student organizations, for their dedication to spreading the word about the dangers of flu and encouraging their peers to get vaccinated,” said Dr. Marie Mazur, Vice President of Global Commercial Development and Policy. “Moving forward, Seqirus is committed to building on this season’s success with college students and continuing the important work of flu prevention for all.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7833751-seqirus-national-award-knockoutflu/
As the season turns from fall to winter, many holiday displays replace pop-up flu vaccine clinics. Yet flu season is not over — it has barely begun. In the 35 years that the Centers for Disease Control and Prevention (CDC) has monitored influenza, February has been the most common month for peak flu activity, including during the 2010-2011 flu season. To share this important information and educate families around the country, Families Fighting Flu is joining the CDC once again during the annual National Influenza Vaccination Week (NIVW) — an observance to promote the importance of flu vaccination as the single best preventative measure against this disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52236-families-fighting-flu-psa-flu-survivor-luke-duvall-flu-prevention
Today, MedImmune Specialty Care division of AstraZeneca (MedImmune Specialty Care) announced it has joined with actress Tia Mowry to raise awareness about the importance of an annual flu vaccination. To kick-off the campaign, MedImmune Specialty Care and Mowry unveiled an online video, “I Insist!” (www.YouTube.com/InsistOnTheMist), which uses comedy to educate busy families about the importance of living a healthy lifestyle and making flu vaccination a priority. For Mowry, this includes vaccination with FluMistQuadrivalent, the first and only FDA-approved needle-free flu vaccine for eligible persons 2-49 years old. FluMist Quadrivalent is administered as a gentle mist sprayed into the nose, where the influenza virus usually enters the body.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63079-medimmune-specialty-care-tia-mowry-flumist-quadrivalent-encourage-flu-shot
Virginia Bioinformatics Institute (VBI), a world-class research institute dedicated to the study of information biology, is using DataDirect Networks (DDN) SFA® high-performance storage engine-based GRIDScaler GPFS parallel file system to perform rapid, accurate Ebola outbreak modeling for the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA).
A team of 30 researchers and scientists on VBI’s Ebola rapid response team initially provided DTRA and West Africa’s Ministries of Health (MOH) with short-term forecasts on vaccine production and disease spread.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7429756-ddn-gridscaler-vbi-ebola/
An international survey conducted by GSK and released for World Meningitis Day shows gaps in the knowledge parents feel they have about meningococcal disease and its potential consequences. Almost 7 in 10 parents said they don’t know enough about the different strains of meningococcal disease and the potential damage they can cause. On average, more than half of parents were either unsure or unaware that there are different types of bacteria that cause the disease.
The survey of 5,000 parents in Brazil, Canada, Germany, Italy and Portugal also shows that out of a list of 14 vaccine-preventable diseases, meningococcal disease is considered by many parents to pose a top three health risk to their children. Fifty-seven percent listed meningococcal disease among the top three health conditions they considered of greatest risk to children followed by Hepatitis B at 34 percent, pneumococcal disease at 27 percent, polio at 25 percent, tetanus at 20 percent and pertussis at 17 percent.
A sudden, potentially life-threatening illness, meningococcal disease kills on average one person every eight minutes worldwide. It typically manifests as bacterial meningitis – an infection of the membrane around the brain and spine; or bacteraemia – a bloodstream infection. The disease progresses rapidly and it can lead to death within 24-48 hours of the first symptoms; globally up to 1 in 10 of those infected may die and in the US about 10-15 percent of people will die.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7814851-gsk-survey-world-meningitis-day/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
The National Meningitis Association (NMA) today announced the launch of a new educational initiative in collaboration with Sanofi Pasteur, the vaccines division of Sanofi, about the importance of the Centers for Disease Control and Prevention’s (CDC’s) recommended second dose of the meningococcal meningitis vaccine (MenACWY) for adolescents at age 16. The 16 Vaccine (The16Vaccine.org) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385951-national-meningitis-association-the-16-vaccine/
